INGELHEIM, Germany – June 7, 2026
Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual agonist survodutide, demonstrating substantial reductions in visceral fat, liver fat, and body weight while preserving lean muscle mass in adults living with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The data, presented at the American Diabetes Association (ADA) 2026 Scientific Sessions and simultaneously published in leading medical journals, reinforce survodutide’s potential to become a next-generation therapy capable of addressing not only weight reduction but also the underlying metabolic abnormalities that drive obesity-related diseases. The findings build on previously announced topline results from the SYNCHRONIZE-1 Phase III trial, where patients achieved up to 16.6% average weight loss over 76 weeks, and further demonstrate the therapy’s ability to selectively target metabolically harmful fat deposits linked to cardiovascular disease, type 2 diabetes, and chronic liver disease. The latest evidence positions survodutide as one of the most closely watched investigational therapies in the rapidly evolving obesity and metabolic health landscape.
Survodutide Shows Targeted Reduction in Harmful Fat Deposits
A detailed pre-specified analysis from the SYNCHRONIZE-1 Phase III study revealed that survodutide produced significant improvements in body composition beyond traditional weight-loss measures. Participants experienced up to 34% reduction in visceral fat, the metabolically active fat surrounding internal organs that is strongly associated with insulin resistance, cardiovascular complications, and chronic inflammation. At the same time, the proportion of lean mass loss accounted for no more than 10.8% of total tissue mass reduction, indicating that the majority of weight loss resulted from fat reduction rather than muscle loss.
Researchers also observed up to 63.1% reduction in liver fat content, highlighting the therapy’s potential to improve liver health and metabolic function. These findings are particularly important because excess visceral and liver fat are considered major drivers of obesity-related diseases, making targeted fat reduction a critical objective in modern metabolic medicine. By addressing these underlying biological factors, survodutide may offer benefits extending far beyond simple weight management.
Phase III MASLD Trial Demonstrates Strong Liver Health Improvements
Advertisement
Additional positive results emerged from the SYNCHRONIZE-MASLD Phase III trial, which evaluated survodutide in adults with obesity or overweight who also had MASLD with evidence of inflammation or fibrosis. The study successfully met both co-primary endpoints, demonstrating significant improvements in liver fat reduction and body weight compared with placebo. According to the results, 84.2% of participants treated with survodutide achieved at least a 30% reduction in liver fat, compared with 24.3% in the placebo group. Patients also experienced up to 12.2% body weight reduction after 48 weeks of treatment.
Particularly noteworthy was the finding that 61% of treated participants achieved liver fat normalization, compared with only 5.7% receiving placebo. Researchers also observed favorable trends in liver-related biomarkers, including reductions in alanine transaminase levels, suggesting improvements in liver inflammation and overall metabolic health. These findings support survodutide’s potential role in addressing the growing global burden of MASLD, a condition affecting a large proportion of people living with obesity.
Expanding Potential Across Obesity and Metabolic Disease
The collective findings from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD highlight the unique dual mechanism of survodutide, which combines GLP-1 receptor activation to reduce appetite and increase satiety with glucagon receptor activity believed to directly reduce liver fat and improve metabolic function. Boehringer Ingelheim believes this differentiated approach may provide broader metabolic benefits than traditional weight-loss therapies. The company is continuing to advance a comprehensive global development program, including additional obesity studies and Phase III trials evaluating survodutide in metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.
Regulatory agencies have already recognized the therapy’s potential, with survodutide receiving FDA Fast Track designation and Breakthrough Therapy designation for MASH-related indications. As obesity and metabolic liver disease continue to rise worldwide, the latest Phase III data suggest that survodutide could emerge as a transformative therapy capable of addressing multiple interconnected metabolic conditions through a single treatment approach.
Source: Boehringer Ingelheim press release
